← CATALYST PHARMACEUTICALS, INC. (CPRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CATALYST PHARMACEUTICALS, INC. (CPRX)
Pharmaceutical Preparations · market cap $3.8B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Catalyst Pharmaceuticals (CPRX) is a profitable rare-disease biopharmaceutical company headquartered in Coral Gables, FL, with 176 employees and a $3.85B market cap. Its commercial anchor is Firdapse (amifampridine phosphate), FDA-approved for Lambert-Eaton myasthenic syndrome (LEMS) in adults and children ≥6, which generated $589M in 2025 revenue with $214M net income. The pipeline extends into vigabatrin for cocaine dependence (Phase 3), and two hemophilia assets (Factor IX and Factor VIIa variants) in Phase 2.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| vigabatrin | Phase 3 | Cocaine Dependence |
| Amifampridine Phosphate | Phase 3 | Lambert Eaton Myasthenic Syndrome |
| Coagulation Factor IX variant | Phase 2 | Hemophilia B |
| Coagulation Factor VIIa variant | Phase 2 | Hemophilia A With Inhibitor |
Price & technical context
3-month
+20.2%
6-month
+35.6%
12-month
+45.7%
52-wk range
$19.13–$31.50
vs 50-day MA
+0.7%
vs 200-day MA
+23.9%
Realized vol
31.8%
Max drawdown
-27.3%
Daily closes through 2026-07-15. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CPRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.